IB
INTEGRATED BIOPHARMA INC (INBP)·Q3 2025 Earnings Summary
Executive Summary
- Q3 FY2025 revenue rose 6.1% year over year to $13.95M, with gross margin expanding to 11.1% and diluted EPS improving to $0.02, reflecting stronger operating leverage versus the prior year .
- Sequentially, revenue increased from $12.61M in Q2 to $13.95M in Q3 and operating margin expanded from 1.6% to 5.3%, indicating improved mix and cost discipline .
- Management continues to highlight progress on customer diversification; the share of revenue from the two largest customers fell to 83% for the nine months ended March 31, 2025 (from 90% a year ago) though concentration remains high .
- No formal guidance was issued and no earnings call transcript was available; press releases remain the primary source of commentary, with macro risks (inflation, tariffs, labor markets) cited as ongoing factors .
What Went Well and What Went Wrong
What Went Well
- Revenue growth and margin expansion: Q3 revenue up 6.1% YoY to $13.95M and gross margin improved to 11.1%, driving operating income to $0.74M and net income to $0.61M .
- Operating leverage: Operating margin increased to 5.3% in Q3 from 3.6% in Q1 and 1.6% in Q2, reflecting improved cost structure and mix .
- Customer diversification momentum: “Our revenues increased by 6.9%... we were able to expand our customer base over the past year and increase our revenue,” per Co-CEOs Riva Sheppard and Christina Kay (nine months ended March 31, 2025) .
What Went Wrong
- Customer concentration remains elevated: Two largest customers accounted for ~83% of nine-month revenue (down from 90% YoY), and were 85% of Q1 quarter revenue, underscoring ongoing dependency risk .
- Limited forward visibility: No guidance ranges provided; commentary is high level, with macro risks cited (inflation, tariffs, tightened labor markets), constraining estimate frameworks .
- Volatility around profitability: Subsequent quarter (Q4 FY2025) posted a net loss despite higher revenue, highlighting sensitivity to cost and mix shifts .
Financial Results
Quarterly Comparison (oldest → newest)
Year-over-Year: Q3 FY2025 vs Q3 FY2024
Estimates vs Actual (S&P Global)
Values retrieved from S&P Global.*
KPIs
Guidance Changes
Management did not issue quantitative guidance ranges in the Q3 FY2025 press release .
Earnings Call Themes & Trends
Note: No earnings call transcript was available; themes reflect press release disclosures .
Management Commentary
- “Our revenues increased by 6.9% in the nine months ended March 31, 2025... we were able to expand our customer base over the past year and increase our revenue” — Co-CEOs Riva Sheppard and Christina Kay .
- “Our goal of diversifying our customer base is reflected in our September quarter numbers from 91% in 2023 to 85% in 2024. We hope to continue this trend as well as grow with our current customers” — Co-CEOs (Q1 FY2025) .
- Macro caution: inflation, tariffs, tightened labor markets, and regulatory changes referenced in forward-looking statements (Q3 FY2025) .
Q&A Highlights
- No earnings call transcript found; no Q&A disclosures were available in our sources. The company’s IR site lists press releases but shows no upcoming events and provides no transcript link .
Estimates Context
- S&P Global shows no active Wall Street consensus for Q3 FY2025 EPS or revenue; coverage appears unavailable for INBP at this time*. Results should be evaluated without an estimates benchmark. Values retrieved from S&P Global.*
- Given the lack of formal guidance and consensus, model updates should emphasize observed sequential margin gains and the trajectory of customer concentration .
Key Takeaways for Investors
- Sequential operating improvements: Q3 operating margin rose to 5.3% from 1.6% in Q2, with EPS improving to $0.02, indicating better execution and mix in core contract manufacturing .
- YoY strength: Revenue +6.1% YoY and net income more than doubled to $0.61M, supported by gross margin expansion to 11.1% .
- Concentration risk persists: Two largest customers still represent ~83% of year-to-date revenue; diversification progress should remain a focal point in underwriting .
- No guidance and limited Street coverage: Absence of formal guidance and lack of consensus estimates increase uncertainty; rely on sequential trends and operational KPIs for near-term positioning .
- Macro sensitivity: Inflation/tariffs and labor market tightness remain stated risks; monitor cost dynamics and potential pass-throughs in contract terms .
- Watch subsequent quarter volatility: Q4 FY2025 net loss despite higher revenue highlights sensitivity to costs and customer order timing; treat Q3 improvements cautiously in near-term forecasts .
- Near-term trading implication: Positive Q3 momentum with margin gains could be supportive, but high customer concentration and macro overhangs argue for balanced risk management until diversification further improves .